Posted by Michael Wonder on 24 Aug 2023
Lynparza plus abiraterone approved in Japan for the treatment of BRCA mutated metastatic castration-resistant prostate cancer
24 August 2023 - Approval based on PROpel Phase 3 trial results which showed Lynparza combination reduced the risk of disease progression or death by 77% versus abiraterone alone.
AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisolone has been approved in Japan for the treatment of adult patients with BRCA mutated castration-resistant prostate cancer with distant metastasis.
